AstraZeneca's plan to unite R&D hubs takes flight

AstraZeneca CEO Pascal Soriot

Looking to tie its two big R&D hubs in Cambridge, U.K., and Gothenburg, Sweden, closer together, AstraZeneca ($AZN) has struck a deal to reserve 20 seats on a Sun Air flight that will make a round-trip journey each day from Monday through Thursday. And it's leaving the remaining 12 seats on each flight up for grabs in the hopes that other scientists will step on board, according to a report in The Telegraph. AstraZeneca CEO Pascal Soriot says the idea here is to get the two hubs to think more as one as AstraZeneca relocates hundreds more scientists into Cambridge. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.